Latest Insider Transactions at Myriad Genetics Inc (MYGN)
This section provides a real-time view of insider transactions for Myriad Genetics Inc (MYGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MYRIAD GENETICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MYRIAD GENETICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 05
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,225
+9.77%
|
$762,075
$27.07 P/Share
|
|
Aug 04
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-9.47%
|
$1,750,000
$35.41 P/Share
|
|
Aug 04
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.48%
|
$1,350,000
$27.07 P/Share
|
|
Aug 03
2021
|
Dennis Langer Director |
SELL
Open market or private sale
|
Direct |
30,000
-25.1%
|
$1,020,000
$34.75 P/Share
|
|
Aug 03
2021
|
Dennis Langer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+20.06%
|
$750,000
$25.39 P/Share
|
|
Aug 03
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-4.93%
|
$1,700,000
$34.27 P/Share
|
|
Aug 03
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+4.57%
|
$1,250,000
$25.38 P/Share
|
|
Aug 03
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,983
-4.41%
|
$524,405
$35.14 P/Share
|
|
Jul 13
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
43,295
-8.04%
|
$1,428,735
$33.72 P/Share
|
|
Jul 13
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,295
+7.09%
|
$1,125,670
$26.49 P/Share
|
|
Jul 12
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-9.52%
|
$1,650,000
$33.55 P/Share
|
|
Jul 12
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.56%
|
$1,300,000
$26.49 P/Share
|
|
Jul 09
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-6.57%
|
$1,600,000
$32.52 P/Share
|
|
Jul 09
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+6.08%
|
$1,200,000
$24.15 P/Share
|
|
Jul 07
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
32,308
-6.19%
|
$1,033,856
$32.14 P/Share
|
|
Jul 07
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,308
+5.58%
|
$840,008
$26.49 P/Share
|
|
Jun 28
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,812
-0.96%
|
$217,984
$32.38 P/Share
|
|
Jun 28
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,812
+0.95%
|
$163,488
$24.15 P/Share
|
|
Jun 25
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
83,372
-9.9%
|
$2,667,904
$32.02 P/Share
|
|
Jun 25
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.89%
|
$950,000
$19.47 P/Share
|
|
Jun 17
2021
|
Daniel K Spiegelman Director |
SELL
Open market or private sale
|
Direct |
3,139
-11.95%
|
$94,170
$30.52 P/Share
|
|
Jun 03
2021
|
Heinrich Dreismann Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+13.33%
|
-
|
|
Jun 03
2021
|
Dennis Langer Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+12.55%
|
-
|
|
Jun 03
2021
|
Lee Nisley Newcomer Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+24.12%
|
-
|
|
Jun 03
2021
|
Daniel K Spiegelman Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+32.85%
|
-
|
|
Jun 03
2021
|
Rashmi Kumar Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+25.89%
|
-
|
|
Jun 03
2021
|
S. Louise Phanstiel Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+13.91%
|
-
|
|
Jun 03
2021
|
Colleen F Reitan Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+24.12%
|
-
|
|
Jun 03
2021
|
Daniel Skovronsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+25.32%
|
-
|
|
May 28
2021
|
Kevin Richard Haas Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
344
+0.61%
|
$5,160
$15.86 P/Share
|
|
May 28
2021
|
Jayne B. Hart Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,082
+1.31%
|
$16,230
$15.86 P/Share
|
|
May 28
2021
|
Daniel K Spiegelman Director |
SELL
Open market or private sale
|
Direct |
7,142
-34.73%
|
$199,976
$28.99 P/Share
|
|
May 27
2021
|
Daniel K Spiegelman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,889
-43.59%
|
-
|
|
May 04
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
19,360
-6.79%
|
$600,160
$31.97 P/Share
|
|
May 04
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,360
+6.36%
|
$367,840
$19.47 P/Share
|
|
Apr 27
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
40,000
-13.08%
|
$1,240,000
$31.47 P/Share
|
|
Apr 27
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+11.56%
|
$760,000
$19.47 P/Share
|
|
Apr 19
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,649
-2.46%
|
$179,523
$27.01 P/Share
|
|
Apr 01
2021
|
Eric Santa Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,420
+50.0%
|
-
|
|
Mar 29
2021
|
Jayne B. Hart Officer |
SELL
Open market or private sale
|
Direct |
58,000
-18.84%
|
$1,740,000
$30.0 P/Share
|
|
Mar 29
2021
|
Jayne B. Hart Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
58,000
+15.54%
|
$1,334,000
$23.08 P/Share
|
|
Mar 24
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,774
+8.79%
|
-
|
|
Mar 24
2021
|
Nicole Lambert Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,556
+17.88%
|
-
|
|
Mar 24
2021
|
Mark Verratti Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,441
+8.95%
|
-
|
|
Mar 24
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,347
+6.78%
|
-
|
|
Mar 24
2021
|
Kevin Richard Haas Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,326
+19.29%
|
-
|
|
Mar 24
2021
|
Paul Parkinson EVP Strategy and Innovation |
BUY
Grant, award, or other acquisition
|
Direct |
10,661
+10.87%
|
-
|
|
Mar 24
2021
|
Benjamin Jackson E.V.P., General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
18,879
+14.99%
|
-
|
|
Mar 24
2021
|
Jayne B. Hart Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,326
+14.26%
|
-
|
|
Mar 24
2021
|
Paul J Diaz President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
159,915
+25.84%
|
-
|